Key Enzymes and Regulation in Gluconeogenesis

Gluconeogenesis runs on four enzymes that catalyze irreversible “bypass” reactions, each tightly controlled by hormones, energy signals, and nutrient availability. While many of the steps in building new glucose simply reverse the reactions used to break it down, these four enzymes exist specifically because the corresponding glycolytic steps are thermodynamically locked in one direction. The interplay among them, and the hormones that dial them up or down, determines how much glucose your liver pumps into the bloodstream between meals, during sleep, and under stress. Getting those dials wrong is central to the fasting hyperglycemia of type 2 diabetes.

The Four Bypass Enzymes

Glycolysis has three irreversible steps, and gluconeogenesis must detour around each of them. The first detour actually requires two enzymes working in sequence, which gives gluconeogenesis four unique catalytic steps in total. Everything else in the pathway borrows the same enzymes glycolysis uses, just running in reverse.

The first bypass converts pyruvate to oxaloacetate using pyruvate carboxylase, then converts oxaloacetate to phosphoenolpyruvate (PEP) using PEP carboxykinase (PEPCK). The second bypass converts fructose-1,6-bisphosphate to fructose-6-phosphate using fructose-1,6-bisphosphatase (FBPase). The third bypass converts glucose-6-phosphate to free glucose using glucose-6-phosphatase (G6Pase). Each of these enzymes responds to different regulatory signals, allowing the body to fine-tune glucose production at multiple checkpoints along the pathway.

Pyruvate Carboxylase and Its Activation by Acetyl-CoA

Pyruvate carboxylase sits inside the mitochondria and performs the first committed step: it attaches a carbon dioxide molecule to pyruvate, producing oxaloacetate. This enzyme is essentially inactive without its key allosteric activator, acetyl-CoA. When fatty acid oxidation is running hard, as it does during fasting, acetyl-CoA accumulates in the mitochondrial matrix and switches pyruvate carboxylase on. Structural studies have shown that acetyl-CoA binding causes large-scale rearrangements in the enzyme’s shape, stabilizing it in a form where its two active sites are brought closer together, which makes the whole catalytic cycle more efficient.¹ Acetyl-CoA also improves the enzyme’s grip on its other substrates, especially bicarbonate and magnesium.²

This design creates an elegant logic gate. Fat burning generates acetyl-CoA, and acetyl-CoA turns on the first step of glucose production. So when your body is pulling energy from fat stores (which happens during a fast or on a low-carbohydrate diet), the gluconeogenic pathway automatically ramps up to keep blood sugar stable. Recent cryo-electron microscopy work has captured the enzyme in multiple transitional states, confirming that acetyl-CoA locks pyruvate carboxylase into a catalytically competent shape that triggers the entire reaction sequence.³ Because of pyruvate carboxylase’s involvement in diabetes and obesity-related metabolic dysfunction, it is now considered a potential therapeutic target.

PEPCK and the Shuttle Problem

Once pyruvate carboxylase makes oxaloacetate inside the mitochondria, that oxaloacetate needs to become PEP, and this is the job of PEPCK. But there is a complication: oxaloacetate cannot simply walk out of the mitochondria. It has to be chemically converted into something transportable, shuttled across the mitochondrial membrane, and then converted back. This is why you sometimes hear about the “malate shuttle” or the “aspartate shuttle” in the context of gluconeogenesis.

PEPCK itself exists in two forms. A cytoplasmic version (PEPCK-C) handles most of the conversion in the cytoplasm after the shuttle delivers oxaloacetate equivalents. But a mitochondrial version (PEPCK-M) also exists and can produce PEP directly inside the mitochondria. That mitochondrial PEP can then leave the mitochondria on its own. Research has highlighted that PEPCK-M, long overlooked, may contribute meaningfully to gluconeogenic flux, and it plays a separate signaling role in insulin-secreting beta cells of the pancreas.⁴

The gene encoding cytoplasmic PEPCK (known as PCK1) is one of the most hormonally regulated genes in all of metabolism. Its transcription surges when glucagon and cortisol are high, and it drops sharply when insulin rises. This makes PEPCK a major control point for how much glucose the liver produces over hours to days, not just minute to minute.

Fructose-1,6-Bisphosphatase and the AMP Brake

Further down the pathway, fructose-1,6-bisphosphatase (FBPase) removes a phosphate group from fructose-1,6-bisphosphate, bypassing the irreversible glycolytic step catalyzed by phosphofructokinase-1. FBPase is powerfully inhibited by AMP, the cellular signal that says “energy is low.” When a cell is struggling for energy, AMP levels climb and FBPase shuts down, which makes sense: if energy is scarce in the liver cell itself, spending ATP to make glucose for export would be counterproductive. Mutagenesis studies on pig kidney FBPase have pinpointed specific residues in the allosteric binding pocket (Lys-112 and Tyr-113) that are critical for AMP binding. Mutating either residue reduces the enzyme’s sensitivity to AMP by more than a thousandfold.⁵

FBPase is also inhibited by fructose-2,6-bisphosphate, a molecule that deserves its own discussion because it acts as the master toggle between glycolysis and gluconeogenesis.

The Fructose-2,6-Bisphosphate Toggle

Fructose-2,6-bisphosphate is not an intermediate of gluconeogenesis or glycolysis. It is purely a regulatory molecule, a signal that controls which direction the traffic flows. High levels of fructose-2,6-bisphosphate activate glycolysis (by stimulating phosphofructokinase-1) and inhibit gluconeogenesis (by suppressing FBPase). Low levels do the opposite.

What makes this system especially clever is that fructose-2,6-bisphosphate is made and destroyed by the same protein. A bifunctional enzyme called PFK-2/FBPase-2 has a kinase domain that synthesizes fructose-2,6-bisphosphate and a phosphatase domain that degrades it.⁶ In the liver, hormonal signals flip the enzyme between its two modes. When glucagon rises during fasting, it triggers a signaling cascade that phosphorylates the liver isoform of PFK-2/FBPase-2 at its N-terminus. That phosphorylation inactivates the kinase side and activates the phosphatase side, so fructose-2,6-bisphosphate levels fall. With the brake off FBPase, gluconeogenesis can proceed.⁷ When insulin rises after a meal, the reverse happens: the kinase side reactivates, fructose-2,6-bisphosphate levels climb, glycolysis is favored, and gluconeogenesis is suppressed.

Glucose-6-Phosphatase and the Final Step

The last bypass enzyme, glucose-6-phosphatase (G6Pase), removes the final phosphate group from glucose-6-phosphate so that free glucose can be released into the bloodstream. This enzyme sits in the membrane of the endoplasmic reticulum (ER), not in the cytoplasm. That means glucose-6-phosphate first has to be transported into the ER lumen by a specific transporter called G6PT before G6Pase can act on it. Structural work has revealed that G6PT adopts an outward-open conformation facing the ER lumen, then undergoes a large rotational swing to shuttle its cargo inside.⁸

Mutations in either G6Pase or G6PT cause glycogen storage disease type I, where the body cannot release glucose from the liver, leading to severe fasting hypoglycemia. The gene encoding G6Pase (G6PC) is one of the two gluconeogenic genes most tightly regulated by hormones, alongside PCK1. Insulin signaling converges on the transcription of both of these genes as a central mechanism for suppressing glucose output from the liver.⁹

Hormonal Control of the Whole Pathway

While each enzyme has its own allosteric regulators, the pathway as a whole is orchestrated by three hormones: glucagon, insulin, and cortisol.

Glucagon, released by the pancreas when blood sugar drops, is the primary “on” signal. It acts through a cAMP signaling cascade that activates a transcription factor called CREB, which binds to the promoters of key gluconeogenic genes (PCK1 and G6PC) and turns them up. Interestingly, recent work in mice fed high-protein diets showed that chronically elevated glucagon initially boosted CREB activity, but over time the pathway shifted to rely on a different transcription factor called FoxO1, suggesting the system can rewire itself under sustained protein intake.¹⁰

Insulin does the opposite. After a meal, rising insulin activates signaling pathways that suppress the transcription of PCK1 and G6PC, effectively telling the liver to stop making glucose because dietary glucose is arriving. When insulin signaling breaks down, as it does in type 2 diabetes, the liver fails to get this “stop” signal and keeps producing glucose even after eating.⁹

Cortisol (and other glucocorticoids) reinforces glucagon’s message. During stress or prolonged fasting, cortisol activates hormone response elements in the promoters of the same gluconeogenic genes, pushing glucose production higher. This is why people on chronic corticosteroid medications often develop elevated blood sugar.

Where Gluconeogenesis Happens Beyond the Liver

The liver handles the lion’s share of gluconeogenesis, but it is not alone. The kidneys and, surprisingly, the small intestine also express the necessary enzymes and can produce glucose. Under normal overnight fasting, the kidney contributes a modest fraction of total glucose output. But during prolonged fasting or in uncontrolled diabetes, the kidney’s contribution jumps dramatically. In rats, renal gluconeogenesis roughly doubled during a 24-hour fast and increased nearly fivefold in diabetic animals compared to the fed state.¹¹

The intestine’s role was revealed in elegant knockout experiments. Mice lacking the ability to produce glucose from the liver experienced a temporary dip in blood sugar but then recovered to near-normal levels, thanks to ramped-up gluconeogenesis in the kidneys and intestine. However, when both liver and intestinal glucose production were knocked out, the mice could not recover and maintained low blood sugar throughout a 48-hour fast.¹² The intestine, it turns out, is not just a passive tube for absorbing nutrients; it participates actively in blood sugar regulation.

The Cahill Cycle and Substrate Supply

Enzymes and hormones set the stage, but gluconeogenesis also needs raw materials. The primary substrates are lactate, alanine, glycerol, and certain amino acids. One of the most important supply routes is the glucose-alanine cycle, also called the Cahill cycle. During fasting, skeletal muscle breaks down protein and releases alanine into the bloodstream. The liver takes up that alanine, strips off the nitrogen, and feeds the carbon skeleton into gluconeogenesis. The resulting glucose goes back to muscle, completing the loop.

Recent stable-isotope tracer studies in humans have shown that during prolonged fasting, the rate at which muscle delivers alanine to the liver actually becomes the bottleneck for glucose production. In other words, the liver’s enzymatic machinery is ready to produce more glucose, but it runs out of substrate from muscle.¹³ This helps explain why prolonged starvation is accompanied by progressive muscle wasting: the body is literally cannibalizing muscle protein to keep blood sugar from crashing.

Gluconeogenesis and Type 2 Diabetes

Excessive gluconeogenesis is a hallmark of type 2 diabetes and a major reason fasting blood sugar runs high in affected individuals.¹⁴ In healthy people, insulin after a meal shuts down hepatic glucose output. In insulin-resistant individuals, that brake is weak: the liver keeps producing glucose on top of whatever is arriving from the meal, driving blood sugar up.

That said, the relationship is not perfectly straightforward. A study measuring gluconeogenic rates in patients with varying severity of type 2 diabetes found that gluconeogenesis was within the normal range in the majority of patients with mild to moderate hyperglycemia. It was primarily in those with more severe disease and significant hepatic insulin deficiency that gluconeogenesis was clearly elevated. The same study concluded that peripheral insulin resistance (reduced glucose uptake by muscle and fat) is at least as important as overproduction of glucose in causing high fasting blood sugar.¹⁵ In practice, both excessive production and poor clearance contribute, but their relative importance shifts as the disease progresses.

Metformin, the most widely prescribed drug for type 2 diabetes, works in part by suppressing hepatic gluconeogenesis. For decades, the precise mechanism was debated. Research using isotope tracers in rats showed that metformin at clinically relevant doses inhibits gluconeogenesis in a redox-dependent manner, specifically reducing the contribution of lactate to glucose production without altering the contribution of alanine. The drug did not appear to work by changing the amounts of gluconeogenic enzymes themselves but rather by shifting the cell’s internal redox balance in a way that slows the pathway.¹⁶

Circadian Rhythms and Meal Timing

Gluconeogenic enzyme expression is not constant around the clock. In mice on a normal diet, the mRNAs encoding key gluconeogenic enzymes show strong daily rhythms, peaking during the late sleep period when the animal has been fasting longest. These rhythms persist even in constant darkness, confirming they are driven by the internal circadian clock rather than just the light-dark cycle. However, timed feeding can override the light cue and re-entrain the rhythm, and mutations in core clock genes dampen the oscillation.¹⁷

For humans, the practical implication is that when you eat may influence how strongly your liver produces glucose. Late-night eating shifts the timing of the fasting window and likely alters the circadian regulation of gluconeogenic genes, though human data on this specific point are still limited. The broader message from the circadian literature is that the liver is not simply a passive responder to hormonal signals; it has an internal schedule that anticipates daily feeding and fasting cycles.

Dietary Effects on Gluconeogenic Flux

Ketogenic and very-low-carbohydrate diets profoundly affect the gluconeogenic machinery. In a study of people with nonalcoholic fatty liver disease placed on a six-day ketogenic diet, overall endogenous glucose production dropped by about 22%, while ketone body production tripled. Fasting insulin fell roughly in half, and insulin resistance improved sharply. Yet the rate of pyruvate carboxylase flux in the liver held steady, suggesting that the enzymatic capacity for gluconeogenesis was maintained even as total glucose output fell, likely because the demand for exported glucose decreased once tissues shifted to burning ketones.¹⁸

High-protein diets have their own effect. Amino acids from dietary protein serve directly as gluconeogenic substrates, and the glucagon response to protein intake can stimulate the pathway independently of low blood sugar. As noted earlier, chronic high-protein feeding in mice shifts the transcriptional control of gluconeogenesis from one set of transcription factors to another, which may have implications for how well drugs that target one specific signaling branch can rein in glucose production.

Carnivores and Constant Gluconeogenesis

Obligate carnivores like domestic cats and dolphins eat diets rich in protein and fat but almost devoid of carbohydrate. Their metabolic baseline resembles what we would consider a pathological state in humans: gluconeogenesis runs constantly, and blood sugar is maintained almost entirely from protein-derived substrates rather than dietary starch or sugar.¹⁹ Genomic comparisons across mammalian lineages have found that multiple carnivore species independently lost the hormone-receptor pair INSL5-RXFP4, which in other animals helps regulate appetite and glucose homeostasis. The loss likely reflects adaptation to irregular feeding patterns and the need for uninterrupted gluconeogenesis between meals.²⁰ These evolutionary snapshots underscore just how central gluconeogenic regulation is to survival across the animal kingdom, and how the same enzymatic toolkit can be tuned to wildly different dietary realities.